BPC-157 and Tamoxifen Interaction

Avoid
Mechanism-based 70% confidence

BPC-157 and Tamoxifen have a potentially harmful interaction with 70% confidence. Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. These compounds primarily affect different organ systems.

Compound Profiles

BPC-157

Body Protection Compound-157 | Pentadecapeptide

Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways..

Half-life: <30 minutes Typical dose: 250-500mcg healing, longevity
vegf anticoagulantcarcinogenic riskpro angiogenicteratogenic
View full profile

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Half-life: ~5-7 days Typical dose: 20-40mg oral daily pct
cyp3a4estrogen receptor anticoagulantcarcinogenic riskhepatotoxicpct agent
View full profile

Combined Organ Load

Blood Vessels
low
Gonads
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the anticoagulant safety flag (BPC-157, Tamoxifen). Monitor accordingly.
2x 2 compounds share the carcinogenic-risk safety flag (BPC-157, Tamoxifen). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (BPC-157, Tamoxifen). Monitor accordingly.

Frequently Asked Questions

Can I take BPC-157 with Tamoxifen?

Combining BPC-157 with Tamoxifen is not recommended. Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision.

Is BPC-157 and Tamoxifen safe together?

This combination carries significant risk. Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. Consult a healthcare professional before combining.

What are the interactions between BPC-157 and Tamoxifen?

Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. This assessment has 70% confidence and is inferred from pharmacological mechanism analysis.

How should I time BPC-157 and Tamoxifen?

BPC-157 has a half-life of <30 minutes and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: BPC-157 vs Tamoxifen

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.